Chemistry is now a front-line part of the FDA argument, not a supporting appendix.
If a submission is leaning on chemical characterization, the file now needs cleaner logic around device representation, extraction strategy, method quality, toxicological interpretation, and how those pieces actually support endpoint decisions.
FDA's draft guidance on chemical analysis for biocompatibility assessment is important because it pushes chemistry work into the center of the biological evaluation story. As of May 2026, the document remains draft, but it is still a strong signal for how FDA expects ISO 10993-18 chemistry and TRA logic to be presented in submissions.
What FDA Published
In September 2024, FDA published the draft guidance Chemical Analysis for Biocompatibility Assessment of Medical Devices. FDA describes it as intended to improve the consistency and reliability of analytical chemistry studies used in premarket submissions. That is the key signal: the agency is not treating chemistry as optional supporting detail. It is treating it as part of the core biocompatibility evidence base.
The same period also brought updated ASCA-related draft guidances from FDA's Division of Standards and Conformity Assessment. Read together, the pattern is clear: FDA wants clearer standard use, stronger test quality, and better chemistry-to-conclusion discipline.
What Changes in Practice
- Device representation matters more: chemistry work performed on the wrong article, wrong configuration, or poorly described test sample is harder to defend.
- Extraction logic needs to be explainable: solvents, durations, temperatures, and surface-area assumptions cannot sit in the appendix without context.
- Compound identification is not the end point: the submission still has to show why detected compounds do or do not change endpoint conclusions.
- TRA linkage gets more important: if toxicological risk assessment is carrying the argument, the path from analytical result to biological conclusion has to be traceable.
- Waiver logic gets less forgiving: a waiver supported by chemistry only works when the chemistry itself is methodologically credible and biologically interpretable.
Which Files Deserve a Recheck Now
- 510(k) packages leaning on ISO 10993-18: especially where chemistry is used to narrow or waive testing.
- Files built around extractables and leachables: coatings, adhesives, additives, colorants, lubricants, and sterilization-related residues often raise the most questions.
- Legacy BERs with older chemistry sections: many older files contain data, but not a clear method-to-risk-to-conclusion chain.
- Point-by-point AI responses: if FDA has already asked about chemistry, rewriting only the summary rarely fixes the underlying weakness.
Pressure-Test Questions Before Submission
- Does the chemistry work reflect the finished patient-contacting device rather than raw materials or an outdated build?
- Would an outside reviewer understand why the extraction conditions are relevant to the device and contact profile?
- Are detected compounds, AET decisions, or unknown handling steps translated into usable toxicological conclusions?
- Does the BER actually change its endpoint logic based on the chemistry, or does the chemistry section sit beside the argument rather than inside it?
- If a test was waived, can the file show why chemistry plus existing evidence is genuinely enough?
If the chemistry section is weak, adding more narrative around it usually does not solve the problem. The chemistry plan, toxicological interpretation, and final biological conclusion have to read as one argument.
Best Next Step for Manufacturers
If the file already exists, start with a focused pressure test rather than a full rewrite. The main question is not whether chemistry data is present. It is whether that data is defensible, device-specific, and clearly tied to the biological evaluation decisions the reviewer is being asked to accept.
Official References
Why this perspective is practical
MedDev Advisory focuses on ISO 10993 biological evaluation, FDA reviewer-facing files, EU MDR technical documentation, and selected CDSCO strategy work. Arvind Rathore's background includes implantable biosensor research at IIT Kanpur and as a Marie Skłodowska-Curie Fellow at INSERM, including hands-on ISO 10993-aligned biocompatibility testing, cytotoxicity, sterilization effects, oxidative stress, and biomaterial-cell interaction work. Read more about Arvind Rathore.
If chemistry is carrying the argument, the chemistry section needs to be reviewer-facing, not appendix-facing.
A focused review can show whether your current chemical characterization and TRA logic are strong enough for the intended FDA submission path.